Antibody Treatments of Inflammatory Arthritis

Author(s): Matthew A. Brown.

Journal Name: Current Medicinal Chemistry

Volume 12 , Issue 25 , 2005

Abstract:

Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.

Keywords: inflammation, il-1, anti-tnf agents, t-cell depletion, cytotoxic-lymphocyte-associated antigen 4, anti-osteoclast therapies

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 25
Year: 2005
Page: [2943 - 2946]
Pages: 4
DOI: 10.2174/092986705774462842
Price: $58

Article Metrics

PDF: 2